Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T13:41:48.928Z.
Calculation as of: 2026-10-06T13:41:48.928Z.
Quote observation: 2026-10-06T13:39:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5275dea95979b783385bf47589e59696b88cb0a7810ad834bc8fbd7b091458bc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$7.77M
EV/Sales Ratio
N/A
TTM Avg
802.02x
3Y Avg
903.36x
5Y Avg
873.57x
Market Cap
$7.93M
EV/Sales Ratio
N/A
TTM Avg
2618.99x
3Y Avg
2618.99x
5Y Avg
2618.99x
Market Cap
$8.26M
EV/Sales Ratio
N/A
TTM Avg
4.01x
3Y Avg
4.01x
5Y Avg
4.01x
Market Cap
$7.44M
EV/Sales Ratio
0.00x
TTM Avg
0.29x
3Y Avg
0.29x
5Y Avg
1.64x
Market Cap
$8.66M
EV/Sales Ratio
0.77x
TTM Avg
0.33x
3Y Avg
0.31x
5Y Avg
0.34x
Market Cap
$6.73M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$9.18M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.84M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $7.77M | N/A | 802.02x | 903.36x | 873.57x |
| GT Biopharma, Inc. (GTBP)vs › | $7.93M | N/A | 2618.99x | 2618.99x | 2618.99x |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.26M | N/A | 4.01x | 4.01x | 4.01x |
| Longeveron Inc. (LGVN)vs › | $7.52M | N/A | 5.06x | 10.00x | 33.75x |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.44M | 0.00x | 0.29x | 0.29x | 1.64x |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.66M | 0.77x | 0.33x | 0.31x | 0.34x |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.73M | N/A | N/A | N/A | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.18M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.71M | N/A | 8.21x | 5.56x | 9.97x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
